Search Site

Claudia A. Chiriboga-Klein, MD, MPH

  • Professor of Neurology and Pediatrics (in the Gertrude H. Sergievsky Center) at CUMC
Claudia A. Chiriboga-Klein, MD, MPH

Dr. Chiriboga is Professor of Neurology and Pediatrics at CUMC and former Interim Director of the Division of Child Neurology, Departments of Neurology and Pediatrics, College of Physicians and Surgeons of Columbia University. She is also former Chief of Pediatric Neurology at Columbia University's affiliate hospital, Harlem Hospital Center.

Dr. Chiriboga was born in Peru and educated in Argentina, where she graduated with Honors from the Faculty of Medicine at the National University of Buenos Aires in 1982. Dr. Chiriboga completed training in pediatrics at St. Luke's-Roosevelt Hospital in 1985. After completing her training in child neurology in 1988 at the Neurological Institute and Babies Hospital of Columbia-Presbyterian Medical Center, Dr. Chiriboga joined the Division of Child Neurology at NewYork-Presbyterian/Columbia University Medical Center. Subsequently, she completed a Neuroepidemiology fellowship at the Gertrude H. Sergievsky Center and received a Master in Public Health from the Mailman School of Public Health, Columbia University. Dr. Chiriboga serves/has served on committees of the NIH, CNS, and ABPN. She is a diplomate of the ABPN in Child Neurology.

Dr. Chiriboga's current research focuses on Spinal Muscular Atrophy (SMA) clinical trials. Past areas of research, including NIH funding, has focused on congenital infections and neurodevelopmental disorders, including cerebral palsy and effects of perinatal exposures. Her clinical practice focuses on neuromuscular disorders as well as developmental, neurobehavioral neurology, and migraine, and on the treatment of spasticity.

Dr. Chiriboga's clinical research, including NIH funding, has focused on congenital infections and neurodevelopmental disorders, including cerebral palsy and effects of perinatal exposures. Her clinical practice focuses on developmental, neurobehavioral neurology and migraine and on the treatment of spasticity.

Departmental Appointments

  • Department of Pediatrics
  • Department of Neurology
    Division of Child Neurology

Board Certifications

  • Child Neurology
  • Neurology with Special Qualification in Child Neurology

Areas of Expertise

  • Developmental Disorder
  • Headache
  • Migraines
  • Movement Disorder

Languages Spoken

(in addition to English)

  • Spanish

Education & Training

  • University of Buenos Aires Medical School
  • Residency: NewYork-Presbyterian Hospital/Columbia University Medical Center
  • Residency: St. Lukes Roosevelt Hospital

Locations

  • Harkness Pavilion

    180 Fort Washington Avenue
    Floor: 5, Suite: 552
    New York, NY 10032
    Phone:
    (212) 305-8549
    For new and current patient appointments, call:
    (646) 426-3876
    Fax:
    (212) 342-6865

Provider Affiliations

  • NewYork-Presbyterian/Columbia
  • NewYork-Presbyterian/Morgan Stanley Children's Hospital

Insurance Programs

Please contact the provider's office directly to verify that your particular insurance is accepted.

  • Aetna [EPO, HMO, Medicare Managed Care, NY Signature, POS, PPO, Signature Administrators, Student Health]
  • Cigna [EPO, Great West, HMO, POS, PPO]
  • Emblem/GHI [HMO, Medicare Managed Care, PPO]
  • Emblem/HIP [ConnectiCare, EPO, Essential Plan, HMO, Medicaid Managed Care, Medicare Managed Care, POS, PPO, Select Care (Exchange), Vytra]
  • Empire Blue Cross Blue Shield [Blue Priority, EPO, HMO, Medicare (Mediblue), NYP Employee Plan, Pathway (Exchange), POS, PPO]
  • Local 1199 [Local 1199]
  • MagnaCare [MagnaCare]
  • Multiplan [Multiplan]
  • Oxford Health Plans [Freedom, Liberty, Medicare Managed Care]
  • POMCO [POMCO]
  • UnitedHealthcare [Columbia University Employee Plan, Compass (Exchange), EPO, Essential Plan, HMO, Medicaid (Community Plan), Medicare Managed Care, POS, PPO]

This provider sees pediatric patients

This provider accepts new patients

Appointment Phone Number: (212) 342-6867

Contact Info

NIH Grants

  • PHASE 3, OPEN-LABEL, SINGLE-ARM, SINGLE-DOSE GENE REPLACEMENT THERAPY CLINICAL TRIAL FOR PATIENTS WITH SPINAL MUSCULAR ATROPHY TYPE 1 WITH ONE OR TWO SMN2 COPIES DELIVERING AVXS-101 BY INTRAVENOUS INFUSION (STRIVE) (P&S Industry Clinical Trial)

    Jul 11 2017 - Jul 11 2022

    PEDIATRIC MDA CARE CENTER (Private)

    Jan 1 2017 - Dec 31 2019

    A PHASE 3, RANDOMIZED, DOUBLE-BLIND, SHAM-PROCEDURE CONTROLLED STUDY TO ASSESS THE CLINICAL EFFICACY AND SAFETY OF ISIS 396443 ADMINISTERED INTRATHECALLY IN PATIENTS WITH LATER-ONSET SPINAL MUSCULAR ATROPHY (P&S Industry Clinical Trial)

    Nov 14 2014 - Nov 14 2019

    A PHASE 3, RANDOMIZED, DOUBLE-BLIND, SHAM-PROCEDURE CONTROLLED STUDY TO ASSESS THE CLINICAL EFFICACY AND SAFETY OF ISIS 396443 ADMINISTERED INTRATHECALLY IN PATIENTS WITH INFANTILE-ONSET SPINAL MUSCULAR ATROPHY (P&S Industry Clinical Trial)

    Aug 14 2014 - Aug 14 2019

    AN OPEN-LABEL STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF ISIS 396443 IN PATIENTS WITH SPINAL MUSCULAR ATROPHY WHO PREVIOUSLY PARTICIPATED IN ISIS 396443-CS2 OR ISIS 396443-CS10 (P&S Industry Clinical Trial)

    Jan 23 2014 - Jan 23 2019

    SPINAL MUSCULAR ATROPHY (SMA) BIOMARKERS IN THE IMMEDIATE POSTNATAL PERIOD OF DEVELOPMENT NN101 (Federal Gov)

    Sep 30 2011 - Aug 31 2018

    SPINAL MUSCULAR ATROPHY (SMA) BIOMARKERS IN THE IMMEDIATE POSTNATAL PERIOD OF DEVELOPMENT NN101 (Federal Gov)

    Sep 30 2011 - Aug 31 2018

    COLUMBIA UNIVERSITY MEDICAL CENTER-WEILL CORNELL MEDICAL CENTER NEXT SITE (Federal Gov)

    Sep 30 2011 - Aug 31 2018

    A STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF MULTIPLE DOSES OF ISIS 396443 DELIVERED INTRATHECALLY TO PATIENTS WITH INFANTILE-ONSET SPINAL MUSCULAR ATROPHY. (P&S Industry Clinical Trial)

    Jun 4 2013 - Jun 4 2018

    AN OPEN-LABEL, DOSE ESCALATION STUDY TO ASSESS THE SAFETY, TOLERABILITY AND DOSE-RANGE FINCING OF MULTIPLE DOSES OF ISIS 396443 DELIVERD INTRATHECALLY TO PATIENTS WITH SMA. (P&S Industry Clinical Trial)

    Mar 14 2013 - Mar 14 2018

    ANOPEN LABEL, ESCALATING DOSE STUDY TO ASSESS THE SAFETY, TOLERABILITY AND DOSE RANGE FINDING OF MULTIPLE INTRATHECAL DOSES OF ISIS 396443 IN PATIENTS WITH SPINAL MUSCULAR ATROPHY (P&S Industry Clinical Trial)

    Oct 25 2012 - Oct 25 2017

    ISIS (P&S Industry Clinical Trial)

    Dec 2 2011 - Dec 2 2016

    SMA FOUNDATION CENTER GRANT (Private)

    Jul 1 2015 - Dec 31 2015

    PEDIATRIC NEUROMUSCULAR CLINICAL RESEARCH NETWORK FOR SMA (Private)

    Jul 1 2012 - Jun 30 2015

    COLUMBIA SMA PROJECT: 4-AP AS A POTENTIAL SMA THERAPEUTIC AGENT AND BIOLOGICAL MECHANISMS OF ACTION (Federal Gov)

    Sep 1 2011 - Aug 31 2014